Roche (SIX: RO, ROG; OTCQX: RHHBY) and Prothena Corporation plc (NASDAQ: PRTA), announced today that they have entered into a
worldwide collaboration to develop and commercialize antibodies that target alpha - synuclein, including PRX002... which is currently in
preclinical development and is expected to enter Phase 1 clinical
trials in patients with Parkinson's disease in 2014.